Needham & Company
-
Needham & Company Maintains a 'Hold' on Hi Tech Pharmacal (HITK); Upside Momentum Stalls Out In 3Q
-
Unusual 11 Midday Movers 01/10: (OMER) (VOXX) (CRL) (PWRD) Higher; (WBMD) (HMA) (GNOM) (HITK) Lower
-
Hi-Tech Pharmacal (HITK) Shares Dip Midday Following Needham Downgrade
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Positive Sense of Déjà Vu as Generic Flonase Drives 1QFY12 Results
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Keeps The Approval Hitting Streak Alive With Another Infield Single
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Sell-Off Overdone
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Positive Surprise as Previously Undisclosed Product is Unveiled
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); FDA Warning Letter Issues Appear in Rearview Mirror as FDA Grants Final Approval to Quixin ANDA
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Accumulate on Weakness - Growth Story Intact With Compelling Valuation
-
Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Weakness Related to FDA Event a Buying Opportunity
-
Needham & Company Initiates Coverage on Hi Tech Pharmacal (HITK) with a Buy; Revenue Momentum Remains Strong

